Anthropic targets life sciences for next growth phase

A life sciences manifesto

Anthropic is preparing for a massive initial public offering next month with a filing that reads like a manifesto for biological research. The company wants to convince investors that it is a crucial part of the next generation of medicinal innovation. By focusing on the human body, the maker of Claude aims to prove the power and worth of AI to the general public.

The company's growth strategy specifically highlights the life sciences sector as a primary target. It notes that the global pharmaceutical spend is expected to exceed $2 trillion by 2026. This provides a massive market for Anthropic's most advanced and expensive models, which are already being used by biotechnology partners and internal researchers.

The filing notes that the company's reach is already significant within the industry. A vast majority of the top pharmaceutical and healthcare firms in the Fortune 500—specifically nine out of ten drug makers and eight out of ten healthcare providers—spent at least $100,000 with Anthropic during a recent year. This suggests that the transition from software tools to life science applications is already underway.

Investing in physical labs

Anthropic is moving beyond just providing software by building physical infrastructure for science. The company started a molecular biology lab in the Bay Area this year to facilitate hands-on research. They also announced a new robotics standard in August designed to let AI systems control various pieces of laboratory equipment.

To bolster its capabilities, Anthropic used $400 million worth of stock in April to purchase the biotech startup Coefficient Bio. These moves indicate a desire to own the tools and data necessary for drug discovery. The company is also aggressively hiring for roles in chemistry, experimental biology, and research engineering to staff these efforts.

The company's hiring reach includes high-paying positions for researchers who can design and manufacture antibodies. These roles offer salaries of $320,000, reflecting the high value placed on specialized biological expertise. By combining AI software with physical labs and robotics, Anthropic is attempting to create a full-stack platform for scientific discovery.

Corporate adoption and optimism

Major pharmaceutical players are already integrating these tools into their daily workflows. For example, the $1.3 trillion company Lilly provides Claude enterprise access to 50,000 of its employees. According to Anthropic, more than 85% of that workforce actively utilizes the tool in their professional tasks.

While the company is optimistic, public sentiment remains more cautious. A recent survey by Anthropic showed that 91% of its own employees believe AI will achieve a Nobel-level discovery by 2030. This stands in stark contrast to only 39% of U.S. adults who share that same level of confidence.

Despite this internal enthusiasm, the practical application of AI in medicine still faces hurdles. To date, no drugs designed entirely by AI have received approval from the FDA. Anthropic is working to bridge this gap by moving its focus from standard software engineering toward the more complex goals of curing diseases.

Leadership and personal goals

CEO Dario Amodei is a primary driver of this shift, often citing his personal history with illness as a motivator. He survived a cancer that would have been untreatable in the 1970s, and his father died of a disease that was cured shortly after his death. These experiences inform his belief that biology is the area where AI can most directly improve human life.

Amodei has written about his vision for AI-enabled research to prevent infectious diseases and eliminate most cancers. He even expressed a hope that these technologies could eventually double the human lifespan. This personal mission aligns with the company's desire to move toward more impactful scientific outcomes.

In a 2024 essay titled 'Machines of Loving Grace,' Amodei elaborated on these themes. He argued that biology is likely the field where scientific progress has the greatest potential to improve human quality of life in a clear and direct way. His goal is to use AI to help prevent all infectious diseases and eliminate the majority of cancers.